CoolSculpting is FDA cleared, not approved. It reached the market through the 510(k) pathway, and a 510(k) clearance means the device was found substantially equivalent to a device already on the market. It is not evidence that the device produces a result. That distinction does most of the work on this page.
Bra fat entered the cleared list on 23 March 2016, under clearance K160259, which added bra fat, back fat and the banana roll in one go. The wording:
"The CoolSculpting System is a skin cooling or heating device. The device is indicated for cold-assisted lipolysis (breakdown of fat) of bra fat, back fat, banana roll, submental area, thigh, abdomen, and flank, or 'love handles' in individuals with a Body Mass Index (BMI) of 30 or less. The device is intended to affect the appearance of visible fat bulges in bra fat, back fat, banana roll, submental area, thigh, abdomen and flank."
The current CoolSculpting Elite, cleared 5 November 2021 under K212707, carries a revised list: upper arm, bra fat, back fat, banana roll, thigh, abdomen and flank at a BMI of 30 or less, with the submental and submandibular areas moved into a separate sentence at a BMI of up to 46.2.
Two details in that wording matter.
The BMI limit for bra fat is 30 or less: A higher ceiling of 46.2 exists in the labelling, but it applies only to the submental and submandibular areas under the chin and jaw. It does not apply here.
The second sentence is about appearance: The device is "intended to affect the appearance of visible fat bulges". There is no weight indication, no BMI-reduction indication and no obesity indication anywhere in the original 2010 grant or the thirteen 510(k) clearances that followed it. The BMI limit is an eligibility ceiling, not a treatment target.
This is the part that is usually left out.
The 2016 clearance that added bra fat is also the document behind the widely quoted "20 to 25 per cent" figure, because it contains FDA's own pooled review of the published literature. That review counted 4,792 cryolipolysis treatments, broken down as: 1,695 on the abdomen, 1,987 on the flanks, 501 on the back, 323 on the inner thigh, 150 on the lateral thigh, 3 on the anterior thigh, 119 submental and 14 on the banana roll.
No bra fat treatments appear in that list: The area was cleared on the strength of data from other areas plus substantial equivalence to a device already cleared — which is exactly what the 510(k) pathway is designed to allow.
So when a clinic tells you CoolSculpting is FDA cleared for bra fat, that is true and it is checkable. When the same page shows you a percentage, that percentage came from abdomens and flanks.
Across the pooled treatments FDA reviewed:
**Mean fat-layer thickness reduction: 20.6 per cent, or 3.9 mm, by ultrasound.**
**Mean caliper reduction: 22.3 per cent.**
Underlying ranges: 10.3 to 25.5 per cent by ultrasound, 14.7 to 23.0 per cent by calipers.
Blinded photo review: 89.7 per cent correct on average.
An independent systematic review of 19 studies found caliper reductions of 14.67 to 28.5 per cent and ultrasound reductions of 10.3 to 25.5 per cent, with no significant effect on blood lipids or liver tests. One of its authors is a consultant for the device maker.
"20 to 25 per cent" is defensible as a mean of pooled means. It is not a per-patient expectation: Someone at the bottom of the range gets around 10 per cent. And it is a reduction in the thickness of the treated fat layer — not in body fat, not in weight, and not in circumference. Those are four different quantities and they are routinely allowed to blur together.
The single strongest independent number comes from a randomised, investigator-blinded split-body trial in 25 people: 14.1 per cent ultrasound fat reduction at 12 weeks on the untampered control side. In that same trial, only 44 per cent of participants recognised any fat loss themselves.
One more thing to name for what it is: the primary effectiveness endpoint in most of these clearances is blinded photo identification — whether an independent reviewer can pick the "before" picture: That is a rating exercise. It is not a measurement of how much fat is gone, and it should never be presented as one. A systematic review of measurement methods in this field concluded that every available method had significant limitations: photographs were subjective, circumference and caliper measurements were confounded, ultrasound was operator-dependent, and MRI was expensive.
CoolSculpting works by drawing tissue into a cooled cup and holding it at a set temperature. Fat cells are more susceptible to cold injury than skin, nerve, vessel and muscle because of their lipid content; the cold triggers an inflammatory reaction in the fat lobules and delayed cell death, and macrophages clear the debris over weeks to months.
The applicators are a family of vacuum cups in different sizes and curvatures rather than one device — the FDA record tracks them through clearances in 2016, 2017, 2019 and 2024 for the CoolAdvantage range and later Elite applicators. No published study of a bra-fat-specific applicator could be located, so how a given clinic fits a cup to that roll is a matter of technique, not of published protocol.
Temperature and time come from the FDA documents rather than marketing: the pivotal submental study ran at −10 °C for 60 minutes and the arm study at −11 °C for 35 minutes. The system's stated floor is −11 °C, with the 2021 Elite summary stating −15 °C and the 2024 Elite summary stating −11 °C — a genuine discrepancy between two FDA documents that has not been resolved. Treatment stops automatically if the interface temperature runs more than 1 °C past target when treating below 5 °C. Since a 2020 clearance, two applicators can run at once.
The unit of sale is the cycle, not the session: One cycle is one applicator placement. In the largest real-world review — 3,262 patients and 18,203 cycles at one multi-site practice — patients had a mean of 5.6 cycles (median 4, range 1 to 177) and a mean of 1.9 sessions (median 1). Those are all-area figures, not bra-fat figures.
Results are judged at 12 weeks after the final treatment in the pivotal studies, and at 16 weeks in the thigh and flank studies. The commonly repeated "8 to 12 weeks" phrasing is marketing language; it is consistent with the trial timelines but no primary document states it.
Durability: The entire long-term evidence base for cryolipolysis is two men, photographed at 2, 5, 6 and 9 years after treatment of one flank with the other flank as their own control. There is no measured long-term cohort.
This is the complication worth understanding before you book, because it is the one that needs surgery.
What it is: A firm, painless, well-defined enlargement of the treated area, appearing months after treatment, in which the fat volume ends up larger than before. It takes the shape of the applicator. It does not resolve on its own. Tissue examined from these cases shows more fat cells, fibrosis and scar tissue, with no sign of malignancy — it is benign, just unwanted and permanent without intervention.
When it appears: The first published case was noticed 3 months after a single abdominal cycle. A later series described firm, well-defined masses at approximately 3 to 6 months. The manufacturer's own safety information says 2 to 5 months. A reference chapter says it generally presents within 12 months.
How often — and this is where the honest answer is a range, not a number:
0.0051 per cent, about 1 in 20,000 cycles: The original 2014 case report and registry figure, now widely regarded as far too low.
0.01 to 0.1 per cent: The manufacturer's current safety statement.
0.018 to 0.048 per cent per cycle: The largest real-world chart review, 18,203 cycles at one practice.
0.05 to 0.39 per cent per cycle: 8 Canadian centres, 2,114 patients and 8,658 cycles.
0.22 per cent of patients, about 1 in 455 (95% CI 0.10 to 0.47): A 2025 meta-analysis of 28 studies and 13,078 patients, containing 29 cases.
0.47 per cent in one single private practice, 0.67 per cent at one academic centre.
About 0.91 per cent, roughly 1 in 110: Reported in the StatPearls chapter as coming from a 2020 systematic review. Attribute that figure to StatPearls; the underlying review has not been checked here. The same chapter also mentions unattributed "recent estimates" of up to 2 per cent.
That spread is roughly a hundredfold, and it is driven by what is being counted — cycles, patients or treatments — and by how long people were followed: The 2025 meta-analysis authors concluded that the incidence "appears to be higher than manufacturer reports", and noted that only 4 of their 28 studies followed patients for 16 weeks or more, which is shorter than the window in which this typically appears. Their pooled figure is probably still an undercount.
Risk factors are contested: Several case series found a strong male predominance — one reported 8 of 11 cases in men, another 55 per cent male despite men being a minority of those treated. But the 2025 meta-analysis found sex-based differences were not statistically significant. One Canadian group found incidence fell by over 75 per cent with newer machine models, with 76.9 per cent of their cases involving older units.
It is corrected surgically: In an 11-case series, 7 were treated surgically — 6 with liposuction alone and 1 with liposuction plus abdominoplasty — and 3 of those 7 needed a second procedure. The guidance in that paper is to wait until the area softens, usually 6 to 9 months after the original treatment, before operating. Further cryolipolysis to the affected area is not recommended and has been shown to make it worse.
FDA's device report database records 11,334 reports under the product code covering these cooling systems, of which 11,096 name CoolSculpting and 1,141 of those name CoolSculpting Elite specifically. Published analyses of that database found cryolipolysis accounted for 38.3 per cent of non-invasive body contouring reports in one period, mostly concerning paradoxical adipose hyperplasia and hernias.
These are counts of reports, not rates: The database has no denominator. Reporting is voluntary, reports are unverified, some are duplicates, many are filed by patients or attorneys rather than clinicians, and volume is strongly influenced by publicity. Report counts jumped from 18 in 2020 to 1,161 in 2021 and 5,499 in 2023, alongside a wave of publicity and legal advertising. That pattern cannot be converted into a percentage of patients and does not by itself show a change in device risk.
There is no dated, sourced price specific to bra fat. Two figures exist with a stated source and date, and they disagree.
RealSelf reports an average of $3,268 with a range of $750 to $8,800, from 1,928 self-reported member reviews, page updated 10 April 2024: This is what patients say they paid for a whole plan, which usually bundles several cycles.
The American Society of Plastic Surgeons published an average surgeon or physician fee of $1,157 for non-surgical fat reduction in 2023: The last year it published a fee for this category at all, as the 2024 report contains no minimally invasive fees. It does not break out CoolSculpting: the same line covers Liposonix, EmSculpt, Vanquish, Zerona and Kybella, and the society says it excludes other related expenses.
The gap between the two is explained by what each is counting, not by a market disagreement. Because pricing is per cycle and cycle counts run from 1 to well over 100, patient totals scatter enormously. Neither figure should be treated as a quote for one area.
Three conditions are absolute contraindications in the manufacturer's own safety information, and all three are cold-mediated blood disorders: cryoglobulinemia, in which certain blood proteins thicken in the cold; cold agglutinin disease, in which cold exposure destroys red blood cells; and paroxysmal cold hemoglobinuria, in which a shift from cold to warm does the same. The logic is not arbitrary — the treatment is prolonged local cold.
Tell your provider in advance if any of the following apply, because the same document lists them as reasons you may not be a suitable candidate:
Cold-sensitivity conditions: cold urticaria, Raynaud's disease, pernio or chilblains
Allergy to isopropyl alcohol, propylene glycol, fructose or glycerin, which are gel pad constituents
Impaired circulation, impaired skin sensation or nerve pain conditions in the area
Open or infected wounds, or eczema, dermatitis or a rash in the area
Bleeding disorders or use of blood thinners
Recent surgery or scar tissue in the area
A hernia in or next to the treatment site
An implanted pacemaker or defibrillator
Chronic pain or an anxiety disorder
Ask how many cycles are being planned and what the total is, since the price is per cycle.
Ask to be photographed and measured at the start, and agree when the result will be judged. The trials judge at 12 weeks after the last treatment.
Note that this consumer safety sheet does not state the BMI limits. Those live in the regulatory clearance, where the limit for bra fat is 30 or less.
Fever with spreading redness, warmth or pus at the treated area. These are signs of a spreading infection and need urgent care the same day.
A firm, well-defined, painless lump appears in the treated area two to six months later, roughly the shape of the applicator, and it is getting bigger rather than smaller: That is the description of paradoxical adipose hyperplasia. It does not resolve on its own, further cryolipolysis makes it worse, and correction is surgical.
Pain begins several days after the treatment rather than during it. Delayed-onset pain was described in a review of 125 patients over 554 procedures as "not uncommon", lasting 3 to 11 days and resolving fully. The number of cycles did not affect whether it happened.
Numbness in the area is still present beyond about 12 weeks. In the arm study FDA reviewed, 4 of 30 patients had numbness lasting past 12 weeks. A prospective Japanese series found numbness persisting around 3 months while pain disappeared within a month.
The skin over the treated area darkens and stays darker. Persistent hyperpigmentation was recorded in both the thigh and flank studies FDA reviewed.
A blister, an open area or a burn appears. One first-degree burn caused a treatment to be stopped in the flank study.
The treated area develops a dent, a hollow or a step rather than a smooth reduction.